Lightcalls.com
 

Over the past several month I've ha...

Over the past several month I've had the pleasure of leading several round-table discussions onward financial topics of interest to those working with high-networth (HNW) clients. principally recently, I asked a cull group of accountants and other professionals a seemingly simple question: Do high-net-worth clients require customized financial fruits and strategies? Are HNW portfolios and financial interests best serv at complex or specialized products tailor-made for the individual? Or docs the "keep it simple" approach work best?

Here's what the cluster had to say.

At the table:

Thane Stenner CIM, FCSI. Fini Vice-President and Investment Advisor, T Stenner arrange CIBC Wood Gundy

Tim Cestnick, FCA, CPA, CFP TEP Bestselling financial author and columnist for the Globe & Mail

Michael Louie, CA, Incorporated Tax Partner. D&H cluster Vancouver



Larry Berrigan, CFA, CAlA. Senior Vice-President. BluMomt Capital

Thane Stennen Tim, give permission to me start the discussion with you. athwart the past several years, it assumes like there's been a chance of new products and strategies introduced that specifically appeal to the high-nct-worth market. And many of these produces are rather complex.

Tim Cestnick, FCA, CPA, CFP TEP: You're right. Gone are the days when wealthy investors awaited to the three basic asset classes to satisfy all their financial straits With the proliferation of alternative investments and income trusts from one side of to the other the last couple of years, the way wealthy investors select to invest has been changing, and will not at any time be the same again.

TS: That unbrokens like a pretty significant shirt.

TC: Basically it's a function of the equity markers we've experienced across the last few years. I know a apportionment of investment counsellors are predicting that equity markets will continue to prompt sideways for a few more years. Many investors who agree with this view have been looking to hedge foundations income trusts, and structured yields to provide market-neutral returns, delicate cash yields, and downside capital protection.

TS: in such a manner how do individuals decide which of these investments is best for them?

TC: The challenge for smart investors is not to determine whether or not they should be in hedge permanent funds income trusts, or structured works because most will find these to be a valuable composing of a well-balanced portfolio. The real challenge will be determining which manufacturers have created the best yields on the market.

TS: And that s where the professional comes in.

TC: Exactly. Those investment advisors who can the couple offer these products to their clients and undertake the just due diligence to determine which are best will do a tremendous service for their clients.

TS: Michael, you work closely with a number of HNW business families. for what cause do you introduce complicated strategies or cropss that a client may not have heard about?

Michael Louie, CA: For HNW families, "complicated" is oftentimes in the eyes of the beholder. It frequently depends on the background of for what cause the person made their money

TS: What do you mean by dint of that?

ML: I can really lay my clients in two broadly defined camps: those who've made their cash in the last ten years, and those who have made it in the last 50 Those in the former category are generally a great deal of more open to new strategies so as hedge funds, retirement compensation arrangements, leveraged annuities-that kind of financial crops With many second and third-generation business families who've been around for decades, they've been fortunate earning their wealth in the "old fashioned" ways. They're les interested in change.

TS: Interesting. in the same manner how do you bring up the topic?

ML: "Selling" the production on its own is not appropriate. I rarely pitch a produce in and of itself. What the HNW individual is seeking is an advisor-either an individual or a team-who will bring to them the ideas suitable for them. What's important is whether the strategy fits the personal circumstances of the individual. You build the case to fit the individual, not the other way around.

TS: in such a manner by introducing a new strategy or crops within the context of the individual's overall financial situation, you make it easier for the individual to understand?

ML: Absolutely. for a like reason far, it's been a prosperous way to run my practice-it just takes a little longer if it be not that a client-focused practice requires a long-term perspective.

TS: At the same time, it shouldn't really be about convincing the client to advance a particular way-clients need to make those decisions for themselves.

ML: convenient point. As chartered accountants, we're in the knowledge business. Remaining objective means presenting the client with all options, to this time still giving the client my opinion forward their opinions. That's the goal. As an accountant, it's essential to bring appropriate strategies and proceedss to the attention of the client. There are situations where keeping it simple is appropriate. If my clients don't take up those strategies, at least I've done my job

TS: Larry, as the senior vice-president of united of the country's top hedge store companies, you have a unique perspective forward the growth of the industry. What's your take onward the increasing popularity of hedge funds?



Other Articles
 -Morphotek will collaborat...
 -Eksigent Technologies nam...
 -The benefits of outsourci...
 -Sartorius Corporation ...
 -In our previous column, w...
 -Efoora appointed Michael ...
 -Affymax appointed Anne-Ma...
 -Traditionally, continuous...
 -New Brunswick Scientific ...
 -The German-American firm ...
 -Don G. Burstyn, formerly ...
 -American patients are mor...
 -Summary Prior to va...
 -BioPharm Editorial Adviso...
 -Australia agreed to spend...
 -The Biotechnology Industr...
 -Ambion, The RNA Company i...
 -Therapies based on living...
 -A recent survey found tha...
 -ViroLogic will acquire Ac...
 -Cardinal Health named Joh...
 -One of the greatest chall...
 -As the president of a sma...
 -Sweden-based Biovitrum wi...
 -Nanogen appointed David L...
 -The Experion Process Know...
 -Although biomedical resea...
 -The Supreme Court of Cana...
 -Netherlands-based DSM Bio...
 -David A. Smoller joined S...
 -A few months ago, I wrote...
 -Panacos Pharmaceuticals w...
 -Karen K. Vaccaro will res...
 -Acceleron Pharma appointe...
 -Two quarterly meetings of...
 -Illinois-based Abbot Labo...
 -FKI Logistics announced t...
 -The following corrections...
 -It its widest definition,...
 -UK-based Xcellsyz will li...
 -Andrew P. Aromando joined...
 -Invitrogen's comprehensiv...
 -Last month, we described ...
 -The Swiss life sciences c...
 -Protein Design Labs (PDL)...
 -Model It HNMR, the newest...
 -Tech transfer, like chang...
 -QLT and Atrix Laboratorie...
 -Dendreon announced Christ...
 -Baxter Pharmaceutical Sol...
 -The biopharmaceutical ind...
 -GlaxoSmithKline announced...
 -Montreal-based Caprion Ph...
 -Xenova Group recently ann...
 -Cole-Parmer's new 192-pag...
 -Over the last decade ther...
 -Benchmark your facility p...
 -As biotechnology organiza...
 -Frederick D. Sancillo, fo...
 -Insmed acquired a recombi...
 -Baxter Pharmaceutical Sol...
 -Model It HNMR, the newest...
 -DA's regulation 21 CFR Pa...
 -Robert P. Ryan joined Ath...
 -A new report from Busines...
 -Biotest offers a complete...
 -Swagelok offers a brochur...
 -Partnering is a global ph...
 -Human Genome Sciences CEO...
 -Shorten the process devel...
 -The licensure of biotechn...
 -Rodger Currie joined Amge...
 -The GEA Filtration Model ...
 -A multi-channel chemistry...
 -From June 6-9, San Franci...
 -Skanska USA Building Inc....
 -New Brunswick Scientific'...
 -AVI BioPharma appointed P...
 -Ambion, The RNA Company, ...
 -"If you want to be a...
 -Xcellerex appointed Susan...
 -Researchers identified th...
 -Cool Spring Business Park...
 -In October 2003, Shenzhen...
 -Laureate Pharma appointed...
 -After a 6-5 vote by Calif...
 -QSourcing, a service of Q...
 -The recent discovery of &...
 -Affymax added Douglas L. ...
 -USDA recently approved tw...
 -BioPharm International is...
 -Serologicals has released...
 -This document by Shenzhen...
 -Robert Bronstein joined A...
 -Gloucester Gains Fujisawa...
 -With more than 30 years o...
 -Pall's SUPRAdisc II depth...
 -In today's competitive ma...
 -Protein Design Labs repor...
 -Charles A. Rice will repl...
 -AstraZeneca's Faslodex (f...
.
© 2006 Lightcalls.com All rights reserved.